Clinical trial · Interventional
Bone Metastasis on the Survival of Gefitinib Effective Patients
Bone Metastasis on the Survival of Gefitinib Effective Patients With Non-small Cell Lung Cancer
NCT03157310CI-TRIAL-00027605completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective clinical trials. The researches aim to analysis whether bone metastasis could affect the survival of NSCLC patients who were effective in Gefitinib treatment over 6 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Overal Survival, Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gefitinib
- description
- Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
- interventionNames
- Drug: Gefitinib
Primary outcomes (1)
- measure
- Overal survival of patients
- timeFrame
- 5 years
- description
- The 5-year survival of NSCLC patients with or without bone metastasis
Secondary outcomes (1)
- measure
- Survival of patients with both bone metastasis and brain metastasis
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. histological and (or) cytological diagnosed NSCLC patients. 2. patient was effective in Gefitinib treatment more than 6 months. 3. whether patient received chemotherapy and other treatment is not restricted. 4. whether patient was detected for EGFR gene mutation was not restricted. Exclusion Criteria: 1. patient with small cell lung cancer. 2. patient without cytology or histopathology diagnosis results. 3. patient with bone metastases cannot rule out other reasons such as inflammation or trauma. 4. patient with poor treatment compliance. 5. patient with incomplete data.
References
Publications (0)
Data not yet available
No reference posted for this study.